Eli Lilly price target raised to $1,281 from $1,182 at Truist

Truist raised the firm’s price target on Eli Lilly (LLY) to $1,281 from $1,182 and keeps a Buy rating on the shares. The firm sees 2026 as a year with growth fueled by expansion of Mounjaro in global markets and the launch of orforglipron in the US, the analyst tells investors in a research note. Eli Lilly’s late-stage assets such as retatrutide and incretin+combo regimens are poised to deliver significant top-line growth, the firm added.